By FieldPulse Editorial · March 24, 2026
Tags: Mergers & Acquisitions, Immunology, Pipeline
Gilead Sciences is acquiring Ouro Medicines for $2.1 billion to gain OM336, a first-in-class BCMAxCD3 T cell engager being developed for autoimmune diseases, signaling the company's intent to expand well beyond its HIV stronghold.
Gilead Sciences announced Monday it will acquire Ouro Medicines for $2.1 billion, securing rights to OM336 — also known as gamgertamig — a novel BCMAxCD3 T cell engager being developed for autoimmune diseases. The transaction marks a deliberate push by Gilead to diversify its revenue base beyond HIV, where it has long dominated but where growth headroom is increasingly constrained. OM336 works by engaging T cells to target BCMA-expressing cells implicated in autoimmune pathology — a mechanism more commonly associated with oncology applications, specifically multiple myeloma, now being explored